⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3709128 | 0.97 | — | — | |
| SCHEMBL4896327 | 0.92 | CA1 (0.33) | — | |
| SCHEMBL22576810 | 0.89 | DGAT1 (0.31) | — | |
| SCHEMBL1795365 | 0.88 | CA2 (0.37) | — | |
| SCHEMBL636443 | 0.88 | — | — | |
| SCHEMBL9215451 | 0.87 | INPP5A (0.33) | — | |
| SCHEMBL3226350 | 0.87 | DGAT1 (0.30) | — | |
| SCHEMBL21602919 | 0.86 | CA2 (0.41) | — | |
| SCHEMBL1044247 | 0.86 | CA2 (0.41) | — | |
| SCHEMBL19693667 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116529246-A | N- [ (1, 3-benzoxazol-2-yl) -heterocycle ] amide derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-08-01 | — | — | CN | claimed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | claimed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | claimed |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-119350323-B | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-113490668-B | Compounds and compositions for the treatment of diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119350323-A | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119330948-A | CYP11A1 inhibitor and application thereof | 西藏海思科制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2025011684-A2 | N-SULFONAMIDE NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND APPLICATION THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004032827-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1337550-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002060926-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |